{"id":4472,"date":"2016-09-28T08:27:44","date_gmt":"2016-09-28T12:27:44","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4472"},"modified":"2016-09-28T08:27:44","modified_gmt":"2016-09-28T12:27:44","slug":"doctors-expect-to-prescribe-sareptas-dmd-drug-despite-insurance-concerns","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4472","title":{"rendered":"Doctors expect to prescribe Sarepta\u2019s DMD drug despite insurance concerns"},"content":{"rendered":"<p>(By Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">D<\/span>efinitive proof may be lacking that the <a href=\"https:\/\/www.statnews.com\/pharmalot\/2016\/09\/19\/sarepta-wins-dmd-drug-approval\/\" target=\"_blank\">newly approved<\/a><sup class=\"footnote\">1<\/sup> Duchenne muscular dystrophy actually works, but most neurologists expect to recommend the medicine for their patients, according to a new survey. <a href=\"https:\/\/www.statnews.com\/pharmalot\/2016\/09\/27\/doctors-sarepta-insurance-coverage-worries\/\" target=\"_blank\">Continue reading article here&#8230;&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Ed Silverman for STAT) Definitive proof may be lacking that the newly approved1 Duchenne muscular dystrophy actually works, but<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-4472","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4472"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4472\/revisions"}],"predecessor-version":[{"id":4473,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4472\/revisions\/4473"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}